The invention of IV Busulfex™ (the intravenous formulation of busulfan) has contributed to a dramatic change in the standard of care for patients undergoing stem cell transplantation for leukemia. It also has greatly improved the outlook for patients with hematologic (blood) and lymphoid cancers.

In March, the lead inventor, Borje S. Andersson, M.D., Ph.D., professor in MD Anderson's Department of Stem Cell Transplantation...